Evidence map›Paper›PMID 33917426›Full record

ArticleCells2021

Quantification of Circulating Cell Free Mitochondrial DNA in Extracellular Vesicles with PicoGreen™ in Liquid Biopsies: Fast Assessment of Disease/Trauma Severity.

Michela Marcatti, Jamal Saada, Ikenna Okereke, Charles E Wade, Stefan H Bossmann, Massoud Motamedi, Bartosz Szczesny

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Review
  5. Article
  6. Discovery of Donor-Derived Exosomal DNA as an Exploratory Biomarker of Kidney Graft Rejection: A Cross-Sectional Study.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Article
  7. Circulating-free DNA: A promising tool for early detection of myocardial infarction.International journal of cardiology. Cardiovascular risk and prevention · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Michela MarcattiDepartment of Neurology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0003-1921-4626
Jamal SaadaDepartment of Anesthesiology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Ikenna OkerekeDepartment of Surgery, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0001-5652-985X
Charles E WadeDepartment of Surgery, University of Texas Health Science Center in Houston, Houston, TX 77003, USA.
Stefan H BossmannDepartment of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS 66160, USA.ORCID 0000-0002-0058-0127
Massoud MotamediDepartments of Ophthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0003-0733-2588
Bartosz SzczesnyDepartment of Anesthesiology, University of Texas Medical Branch, Galveston, TX 77555, USA.ORCID 0000-0002-6196-3981
The University of Texas Medical Branch at Galveston · USThe University of Kansas Cancer Center · USThe University of Texas Health Science Center at Houston · US

Funding

National Science Foundation 1804422
6 · The paper itself

Abstract

The analysis of circulating cell free DNA (ccf-DNA) is an emerging diagnostic tool for the detection and monitoring of tissue injury, disease progression, and potential treatment effects. Currently, most of ccf-DNA in tissue and liquid biopsies is analysed with real-time quantitative PCR (qPCR) that is primer- and template-specific, labour intensive and cost-inefficient. In this report we directly compare the amounts of ccf-DNA in serum of healthy volunteers, and subjects presenting with various stages of lung adenocarcinoma, and survivors of traumatic brain injury using qPCR and quantitative PicoGreen™ fluorescence assay. A significant increase of ccf-DNA in lung adenocarcinoma and traumatic brain injury patients, in comparison to the group of healthy human subjects, was found using both analytical methods. However, the direct correlation between PicoGreen™ fluorescence and qPCR was found only when mitochondrial DNA (mtDNA)-specific primers were used. Further analysis of the location of ccf-DNA indicated that the majority of DNA is located within lumen of extracellular vesicles (EVs) and is easily detected with mtDNA-specific primers. We have concluded that due to the presence of active DNases in the blood, the analysis of DNA within EVs has the potential of providing rapid diagnostic outcomes. Moreover, we speculate that accurate and rapid quantification of ccf-DNA with PicoGreen™ fluorescent probe used as a point of care approach could facilitate immediate assessment and treatment of critically ill patients.

Indexed as

Liquid BiopsySeverity of Illness IndexAdenocarcinoma of LungAdultAgedBrain Injuries, TraumaticCell-Free Nucleic AcidsDNA, MitochondrialExtracellular VesiclesFemaleHumansLung NeoplasmsMaleMiddle AgedOrganic ChemicalsCell-Free Nucleic AcidsDNA, MitochondrialOrganic ChemicalsPicoGreencirculating cell free DNAextracellular vecisclesmitochondrial DNAPicoGreenTM stainingtrauma severitytraumatic brain injury

Identifiers

PMID33917426
PMCPMC8067453
OpenAlexW3149735005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.